13F Holdings
中文EN

BNTC Benitec Biopharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1808898 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-18.4%
TTM EPS YoY4.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-37.6%
ROA-36.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.3%
Debt / equity0.00x
Current ratio19.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.34x
Accruals ratio-23.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue——$0$75,000$73,000
R&D expense$23.39M$18.33M$15.61M$12.77M$11.27M
SG&A expense$27.80M$23.43M$6.99M$6.38M$6.65M
Operating income-$51.19M-$41.77M-$22.49M-$19.08M-$17.85M
Pretax income-$45.34M-$37.18M-$21.04M-$18.95M-$17.37M
Income tax$0————
Net income-$45.55M-$37.92M-$21.75M-$19.56M-$18.21M
EBITDA-$51.13M-$41.70M-$22.40M-$18.95M-$17.69M
EPS (basic)-0.98-1.05-1.22-14.12-37.88
EPS (diluted)-0.98-1.05-1.22-14.12-37.88
Weighted avg. shares (diluted)46.56M36.21M18.36M1.39M480,688
Balance sheet
Cash & equivalents$179.97M$97.86M$50.93M$2.49M$4.08M
Current assets$181.69M$98.52M$51.67M$3.73M$4.82M
PP&E, net$178,000$131,000$179,000$87,000$222,000
Total assets$182.62M$99.59M$52.21M$4.46M$5.97M
Current liabilities$5.34M$1.80M$4.92M$3.98M$2.53M
Total liabilities$5.61M$2.30M$4.96M$4.26M$3.09M
Shareholders' equity$177.01M$97.30M$47.25M$202,000$2.88M
Shares outstanding34.42M26.25M10.09M1.67M480,688
Cash flow statement
Operating cash flow-$16.52M-$23.59M-$19.40M-$18.01M-$15.90M
Capital expenditure$105,000$18,000$179,000$1,000$13,000
Free cash flow-$16.62M-$23.61M-$19.58M-$18.01M-$15.91M
Investing cash flow-$105,000-$18,000-$179,000-$1,000-$13,000
Financing cash flow$98.98M$70.48M$68.03M$16.02M—
Depreciation & amortization$58,000$66,000$87,000$136,000$167,000
Stock-based compensation$26.41M$17.43M$830,000$452,000$870,000

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.